Comparative Study of the Effect of Various Forms of Quercetin on Experimental Diabetes

Open access


Background and aims: Diabetes mellitus (DM) is a multifactorial metabolic disorder characterized by hyperglycaemia caused by insulin deficiency or insulin resistance. It is a global public health problem. This study aimed to determine specific pharmacological effect of quercetin in water soluble and liposomal preparations in experimental diabetes mellitus. Material and methods: We examined the effect of Corvitin and Lipoflavone (at the dose of 10 mg / kg body weight) in a comparative study in white rats with type 1 diabetes and type 2 diabetes coupled with obesity. To simulate the forms of diabetes mellitus most analogous to those in humans we used Streptozotocin at the doses of 30 mg / kg and 50 mg / kg. We tested the levels of glucose, glycosylated hemoglobin, C-reactive protein, and interleukins 6 and 4 in the blood. Results: In animals with type 1 and type 2 diabetes Lipoflavone significantly reduces glucose and glycosylated hemoglobin levels compared to the rats treated with Corvitin. When administered to animals with diabetes, the effect of quercetin in liposomal form on the concentrations of IL-6, IL-4 and Creactive protein is also larger compared to the water-soluble form. Conclusions: Water soluble quercetin preparation Corvitin and to a larger extent liposomal preparation of this flavonoid, Lipoflavone, show anti-inflammatory effect and restore key parameters of carbohydrate metabolism in experimental type 1 diabetes mellitus and type 2 diabetes coupled with obesity, reducing blood glucose and glycosylated hemoglobin levels.

1. Marushchak M, Lisnianska N, Krynytska I, Chornomydz I. The mechanisms of apoptosis initiation in rats with chronic enterocolitis combined with streptozotocin-induced diabetes. Georgian Med News 9(270): 125-130, 2017.

2. Posokhova KA, Stechyshyn IP, Pidhirnyy VV. Impact of quercetin substances on the state of myocardium in 2 type dіabetіs. Achievements of clinical and experimental medicine 2: 17-21, 2014.

3. Urbanovych A, Suslyk H. Prognosis of ischaemic heart disease in patients with newly diagnosed DM type 2 by logistic regression. Wiad Lek 71(3): 691- 694, 2018.

4. Demikhova N, Chernatska O, Mazur T et al. Markers of cardiovascular complications in patients with type 2 diabetes mellitus and arterial hypertension. Bangladesh Journal of Medical Science 17(2): 319-322, 2018.

5. Krynytska I, Marushchak M. The indices of nitric oxide system in rats with carrageenan-induced enterocolitis combined with diabetes mellitus. Rom J Diabetes Nutr Metab Dis 25(3): 283-288, 2018.

6. Guzyk MM, Dyakun KO, Yanytska LV et al. Inhibitors of Poly(ADP-Ribose)Polymerase-1 as Agents Providing Correction of Brain Dysfunctions Induced by Experimental Diabetes. Neurophysiology 49(3): 183-193, 2017.

7. Korda MM. Status of the antioxidant, monooxygenase and humoral immune system of the body in d-galactosamine hepatitis. Ukrain'skyi Biokhimichnyi Zhurnal 68(1): 72-75, 1996.

8. Posokhova KA, Zozuliak NB, Cherniashova VV, Stechyshyn IP. Method of experimental obesity modeling. Patent of Ukraine 92289: 15, 2014.

9. Moyer VA. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157(5): 373-378, 2012.

10. Council of Europe Strasbourg. European convention for the protection of vertebrate animals used for experimental and other scientific purposes 123: 52, 1986.

11. Sergienko VO, Sergienko OO, Efimov AS. Pathogenesis of diabetic cardiomyopathy (literature review and original research). Journal of AMS 16(2): 225-244, 2010.

12. Boychuk TM, Tolstanov OK, Grytsyuk MI, Gorenki AI. Protein glycosylation in diabetes mellitus: formation and pathogenetic effects (literature review). Current issues of transportation medicine: environment; professional health; pathology 3: 52-59, 2013.

13. Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes 21(2): 109-120, 2014.

14. Imessaoudene A, Merzouk H, Berroukeche F et al. Beneficial effects of quercetin-iron complexes on serum and tissue lipids and redox status in obese rats. J Nutr Biochem 29: 107-115, 2016.

15. Borikov OY. Antioxidant activity of molecules from different flavonoid groups in vitro. Pharmacy Bulletin 3(63): 73-75, 2010.

16. Ashraf JM, Shahab U, Tabrez S, Lee EJ, Choi I, Ahmad S. Quercetin as a finer substitute to aminoguanidine in the inhibition of glycation products. Int J Biol Macromol 77: 188-192, 2015.

17. Kim YJ, Park W. Anti-Inflammatory Effect of Quercetin on RAW 264.7 Mouse Macrophages Induced with Polyinosinic-Polycytidylic Acid. Molecules 21(4): 450, 2016.

18. Agrawal AD. Pharmacological activities of flavonoids: a review. International Journal of Pharmaceutical Sciences and Nanotechnology 4(2): 1394-1398, 2011.

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

The Journal of Romanian Society of Diabetes Nutrition and Metabolic Diseases

Journal Information

CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 102 102 14
PDF Downloads 63 63 10